IGF1 and Parkinson disease: In this fashion, it could be reasonable to think in a combined therapy with estrogens and IGF-1, since both molecules can cross the blood–brain barrier activating the IGF-1 signaling pathway to exert its favorable actions in brain and also to prevent α-synuclein aggregation (Lewy body deposition), thus avoiding PD development.